SOURCE: SpectraScience, Inc.
SAN DIEGO, CA--(Marketwire - Oct 15, 2012) - SpectraScience, Inc. (OTCQB: SCIE), a San Diego-based medical device company, announced that its WavSTAT Optical Biopsy System will be featured in the PENTAX Medical booth at the United European Gastroenterology Week Conference (UEGW) in Amsterdam, October 20-25, 2012. PENTAX will also highlight the benefits of WavSTAT during a dinner presentation to more than 150 European physicians and medical professionals held during UEGW.
In June 2012, SpectraScience signed an exclusive five-year agreement with PENTAX Europe GmbH to distribute its WavSTAT Optical Biopsy System for use in colorectal cancer screening and diagnosis. The agreement, which includes the Company's new WavSTAT4 console and the disposable optical biopsy forceps, covers Europe as well as Turkey, Saudi Arabia, and South Africa. PENTAX is a leading provider of minimally invasive surgical devices, including flexible endoscopes, which are used with the WavSTAT System during screening for colorectal cancer.
"We are looking forward to supporting PENTAX at the conference, and seeing firsthand how physicians respond to WavSTAT's capabilities and benefits," said Michael Oliver, SpectraScience's Chief Executive Officer. "UEGW is an excellent venue to complement our recent training sessions with PENTAX sales representatives in key initial markets, including Germany, France, the United Kingdom and The Netherlands. Because UEGW is a pan-European event, WavSTAT will be introduced to customers in additional smaller markets, and we expect to get feedback that will help guide the product launch strategy. Following UEGW we plan to proceed with PENTAX sales force training in the Scandinavian countries, and then in southern Europe."
About United European Gastroenterology Week
The United European Gastroenterology Week (UEGW) has been organized annually since 1992 and has become the largest and most prestigious GI meeting in Europe. The 2012 Conference program will include a celebration of the UEG Week and UEG; top journal editors summarizing advances in combatting digestive diseases over the last 20 years; and leaders in research and clinical practice describing what the future may hold next in their fields. Special themes will include the modern role of multidisciplinary care and the effect of obesity and alcohol on GI and liver disease. There will also be two full days of live endoscopy, a focus on Inflammatory Bowel Disease (including treatment advances), the expanding role of gastroenterologists in GI oncology and a plethora of lectures by established names and rising stars on state-of-the-art treatments and technologies
About SpectraScience, Inc.
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets light-based analysis systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically diagnose tissue and provide the physician with an immediate result. With approval for sale under the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, acceptance of the Company's products and services in the marketplace, competitive factors, dependence upon third-party vendors, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.